These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 19671737)

  • 21. The insulin-like growth factor 1 receptor in cancer: old focus, new future.
    Hartog H; Wesseling J; Boezen HM; van der Graaf WT
    Eur J Cancer; 2007 Sep; 43(13):1895-904. PubMed ID: 17624760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The therapeutic potential of agents targeting the type I insulin-like growth factor receptor.
    Zhang H; Yee D
    Expert Opin Investig Drugs; 2004 Dec; 13(12):1569-77. PubMed ID: 15566314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IRS2 copy number gain, KRAS and BRAF mutation status as predictive biomarkers for response to the IGF-1R/IR inhibitor BMS-754807 in colorectal cancer cell lines.
    Huang F; Chang H; Greer A; Hillerman S; Reeves KA; Hurlburt W; Cogswell J; Patel D; Qi Z; Fairchild C; Ryseck RP; Wong TW; Finckenstein FG; Jackson J; Carboni JM
    Mol Cancer Ther; 2015 Feb; 14(2):620-30. PubMed ID: 25527633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies.
    Simpson A; Petnga W; Macaulay VM; Weyer-Czernilofsky U; Bogenrieder T
    Target Oncol; 2017 Oct; 12(5):571-597. PubMed ID: 28815409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment.
    Bohula EA; Playford MP; Macaulay VM
    Anticancer Drugs; 2003 Oct; 14(9):669-82. PubMed ID: 14551500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potent and selective cyclohexyl-derived imidazopyrazine insulin-like growth factor 1 receptor inhibitors with in vivo efficacy.
    Jin M; Kleinberg A; Cooke A; Gokhale PC; Foreman K; Dong H; Siu KW; Bittner MA; Mulvihill KM; Yao Y; Landfair D; O'Connor M; Mak G; Pachter JA; Wild R; Rosenfeld-Franklin M; Ji Q; Mulvihill MJ
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1176-80. PubMed ID: 21251824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The possible role of insulin-like growth factor-1 in osteosarcoma.
    Li YS; Liu Q; He HB; Luo W
    Curr Probl Cancer; 2019 Jun; 43(3):228-235. PubMed ID: 30217668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical development of inhibitors of the insulin-like growth factor receptor in oncology.
    Gualberto A; Pollak M
    Curr Drug Targets; 2009 Oct; 10(10):923-36. PubMed ID: 19663769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy.
    Zha J; Lackner MR
    Clin Cancer Res; 2010 May; 16(9):2512-7. PubMed ID: 20388853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase.
    Sabbatini P; Rowand JL; Groy A; Korenchuk S; Liu Q; Atkins C; Dumble M; Yang J; Anderson K; Wilson BJ; Emmitte KA; Rabindran SK; Kumar R
    Clin Cancer Res; 2009 May; 15(9):3058-67. PubMed ID: 19383820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin-like growth factor receptor-1 (IGF-1R) expression in normal breast, proliferative breast lesions, and breast carcinoma.
    Bhargava R; Beriwal S; McManus K; Dabbs DJ
    Appl Immunohistochem Mol Morphol; 2011 May; 19(3):218-25. PubMed ID: 21217522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Specific targeting of insulin-like growth factor 1 receptor signaling in human estrogen dependent breast cancer cell by a novel tyrosine-based benzoxazepine derivative.
    Chakravarti B; Siddiqui JA; Dwivedi SK; Deshpande S; Samanta K; Bhatta RS; Panda G; Prabhakar YS; Konwar R; Sanyal S; Chattopadhyay N
    Mol Cell Endocrinol; 2011 May; 338(1-2):68-78. PubMed ID: 21457754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting insulin-like growth factor signaling: rational combination strategies.
    Olmos D; Basu B; de Bono JS
    Mol Cancer Ther; 2010 Sep; 9(9):2447-9. PubMed ID: 20807783
    [No Abstract]   [Full Text] [Related]  

  • 34. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions.
    Gualberto A; Pollak M
    Oncogene; 2009 Aug; 28(34):3009-21. PubMed ID: 19581933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel mechanisms of regulation of IGF-1R action: functional and therapeutic implications.
    Worrall C; Nedelcu D; Serly J; Suleymanova N; Oprea I; Girnita A; Girnita L
    Pediatr Endocrinol Rev; 2013 Jul; 10(4):473-84. PubMed ID: 23957198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor.
    Mulvihill MJ; Cooke A; Rosenfeld-Franklin M; Buck E; Foreman K; Landfair D; O'Connor M; Pirritt C; Sun Y; Yao Y; Arnold LD; Gibson NW; Ji QS
    Future Med Chem; 2009 Sep; 1(6):1153-71. PubMed ID: 21425998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiation and new molecular agents, part II: targeting HDAC, HSP90, IGF-1R, PI3K, and Ras.
    Chinnaiyan P; Allen GW; Harari PM
    Semin Radiat Oncol; 2006 Jan; 16(1):59-64. PubMed ID: 16378908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
    Tanno B; Mancini C; Vitali R; Mancuso M; McDowell HP; Dominici C; Raschellà G
    Clin Cancer Res; 2006 Nov; 12(22):6772-80. PubMed ID: 17121898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting insulin-like growth factor 1 receptor in sarcomas.
    Scotlandi K; Picci P
    Curr Opin Oncol; 2008 Jul; 20(4):419-27. PubMed ID: 18525338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors.
    Reidy-Lagunes DL; Vakiani E; Segal MF; Hollywood EM; Tang LH; Solit DB; Pietanza MC; Capanu M; Saltz LB
    Cancer; 2012 Oct; 118(19):4795-800. PubMed ID: 22437754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.